These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26120010)

  • 41. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein.
    Robertson SM; Luo X; Dubey N; Li C; Chavan AB; Gilmartin GS; Higgins M; Mahnke L
    J Clin Pharmacol; 2015 Jan; 55(1):56-62. PubMed ID: 25103957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of post-marketing safety and surveillance data for oral contraceptives containing norgestimate and ethinyl estradiol.
    Lippman JS; Shangold GA
    Int J Fertil Womens Med; 1997; 42(4):230-9. PubMed ID: 9309456
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG; Dai Y
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use.
    Baerwald AR; Olatunbosun OA; Pierson RA
    Contraception; 2004 Nov; 70(5):371-7. PubMed ID: 15504375
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
    Kasserra C; Li J; March B; O'Mara E
    Clin Ther; 2011 Oct; 33(10):1503-14. PubMed ID: 22015327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disposition of norgestimate in the presence and absence of ethinyl estradiol after oral administration to humans.
    Weintraub HS; Abrams LS; Patrick JE; McGuire JL
    J Pharm Sci; 1978 Oct; 67(10):1406-8. PubMed ID: 702290
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea.
    Grinspoon SK; Friedman AJ; Miller KK; Lippman J; Olson WH; Warren MP
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3651-6. PubMed ID: 12915650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives.
    Hampton RM; Zhang HF; Barnowski C; Wan GJ
    Contraception; 2008 Jun; 77(6):415-9. PubMed ID: 18477490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor.
    Garg V; Shen J; Li C; Agarwal S; Gebre A; Robertson S; Huang J; Han L; Jiang L; Stephan K; Wang LT; Lekstrom-Himes J
    Clin Transl Sci; 2019 May; 12(3):267-275. PubMed ID: 30694595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
    Creasy GW; Fisher AC; Hall N; Shangold GA
    J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
    Derks M; Abt M; Parr G; Meneses-Lorente G; Young AM; Phelan M
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1135-45. PubMed ID: 20738227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
    Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study.
    Warren MP; Miller KK; Olson WH; Grinspoon SK; Friedman AJ
    Contraception; 2005 Sep; 72(3):206-11. PubMed ID: 16102557
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lomitapide.
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):347-52. PubMed ID: 21846156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child.
    Chacra APM; Ferrari MC; Rocha VZ; Santos RD
    J Clin Lipidol; 2019; 13(3):397-401. PubMed ID: 30948303
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lomitapide for the treatment of hypercholesterolemia.
    Berberich AJ; Hegele RA
    Expert Opin Pharmacother; 2017 Aug; 18(12):1261-1268. PubMed ID: 28598687
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
    Freise KJ; Shebley M; Salem AH
    J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ziritaxestat Drug-Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition.
    Helmer E; Karimian N; Van Assche K; Seghers I; Le Tallec S; Cherala G; Scott G; Namour FS
    Clin Pharmacol Ther; 2022 Oct; 112(4):901-908. PubMed ID: 35713964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.